A Phase 1, Open-Label Study to Determine the Relative Bioavailability of LY3454738 in Healthy Participants
Latest Information Update: 04 Jun 2024
At a glance
- Drugs Ucenprubart (Primary)
- Indications Atopic dermatitis; Chronic urticaria; Immunological disorders
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
Most Recent Events
- 29 May 2024 Status changed from active, no longer recruiting to completed.
- 25 Mar 2024 Status changed from recruiting to active, no longer recruiting.
- 23 Jan 2024 Status changed from not yet recruiting to recruiting.